期刊文献+

河南汉族癫癎儿童UGT1A6 A541G基因多态性与丙戊酸血药浓度相关性研究 被引量:10

Effect of UGTIA6 A541G genetic polymorphism on the metabolism of valproic acid in Han epileptic children from Henan
原文传递
导出
摘要 目的检测尿苷二磷酸葡糖醛酰转移酶(UGT)1A6 A541G基因多态性在汉族癫癎患儿中的分布和突变频率,探讨UGT1A6 A541G突变各基因型与丙戊酸血药浓度的关系。方法气相色谱法测定丙戊酸血药浓度,PCR-RFLP技术检测UGTIA6 A541G基因多态性,PCR扩增产物直接测序验证基因型检测方法的可靠性。结果 147例汉族癫癎患儿中UGTIA6541位点的基因型AA、AG、GG分别为76例、65例和6例。服用单位剂量(mg/kg)引起的血药浓度AA基因型患儿为3.91±1.57μg/mL,AG基因型患儿为3.59±1.39μg/mL,GG基因型患儿为3.73±1.28μg/mL。AG、GG基因型患儿血药浓度较AA基因型患儿偏低,但差异无统计学意义。结论 UGT1A6A541G基因多态性与丙戊酸的血药浓度无显著相关性,临床上个体血药浓度的差异可能是多种因素共同作用的结果 。 Objective To investigate the distribution and frequency of UGTIA6 A541G genetic polymorphism in Han epileptic children from Henan and to evaluate the effect of UGTIA6 A541G genetic polymorphism on serum concentrations of valproic acid. Methods The method of gas chromatography was used to assay serum concentrations of valproic acid. UGTIA6 A541G genetic polymorphism was screened by PCR-RFLP. Direct sequencing was used to confirm the expected sequences of each genotype. Results The genotypic frequencies of UGTIA6 A541G were as follows: AA in 76 cases, AG in 65 cases and GG in 6 cases. The mean values of serum concentrations of valproic acid in patients with A541G AA, AG and GG were 3.91 + 1.57, 3.59 -+ 1.39 and 3.73 + 1.28 Ixg/mL, respectively (dose-adjusted trough concentration on a mg/kg basis). There were no significant differences in serum concentrations of valpmic acid among the three groups. Conclusions UGT1A6 A541G gene polymorphism does not influence serum concentrations of valproie acid in Han epileptic children. Individual differences in serum concentrations of valproic acid may be attributed to many factors.
出处 《中国当代儿科杂志》 CAS CSCD 北大核心 2010年第6期429-432,共4页 Chinese Journal of Contemporary Pediatrics
关键词 UGT1A6 基因多态性 丙戊酸 癫癎 儿童 UGTIA6 Genetic polymorphism Valproie acid Epilepsy Child
  • 相关文献

参考文献18

  • 1Stokes T, Shaw EJ, Juarez-Garcia A, Camosso-Stefinovie J, Baker R (2004). Clinical Guidelines and Evidence Review for the Epilepsies: diagnosis and management in adults and children in primary and secondary care. London: Royal College of General Prac- titioners, http ://www. nice. org. uk/.
  • 2Sanchez-Alcaraz A, Quintana MB, Lopez E, Rodrlguez I. Valproic acid clearance in children with epilepsy [J]. Clin Pharm Ther, 1998, 23(1) :31-34.
  • 3郑惠良,刘文弟,祁元明,杨莹,黄喜顺,景学医,常爱武.丙戊酸钠治疗不同年龄的癫痫血药浓度研究[J].实用儿科临床杂志,1998,13(3):168-168. 被引量:10
  • 4von Ahsen N, Richter M, Grupp C, Ringe B, Oellerich M, Armstrong VW. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V co allele) on doseadjusted eyclosporin Atrough ncentrations or rejection incidence in stable renal transplant recipients [ J]. Clin Chem, 2001,47 (6) : 1048-1052.
  • 5Nagar S, Zalatoris JJ, Blanehard RL. Human UGT1 A6 pharmacogenetics : identication of a novel SNP, characterization of allele frequencies and functional analysis of recombinant allozymes in human liver tissue and in cultured cells [ J ]. Pharmacogeneties, 2004, 14(8) :487-499.
  • 6Ethell BT, Anderson GD, Burchell B. The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP-glucuronosyltransferases [ J ]. Biochem Pharmacol, 2003, 65 ( 9 ) : 1441-1449.
  • 7Yamagata T, Momoi MY, Mural K, Ikematsu K, Suwa K, Sakamoto K, et al. Penipenem-betamipron and decreases in serum valproic acid concentration [ J ]. Ther Drug Monit, 1998, 20 (4) : 396-400.
  • 8Tukey RH, Strassburg CP. Human UDP-glucuronosyltransferase: metabolism, expression, and disease [ J ]. Annu Rev Pharmacol Toxicol, 2000, 40:581-616.
  • 9Urawa N, Kobayashi Y, Araki J, Sugimoto R, Iwasa M, Kaito M, et al. Linkage disequilibrium of UGT1A1 * 6 and 15GT1A1 * 28 in relation to UGT1A6 and UGT1A7 polymorphisms [ J]. Oncol Rep, 2006, 16(4) :801-806.
  • 10Ciotti M, Marrone A, Potter C, Owens IS. Genetic polymorphism in the human UGT1 A6 (planar phenol) UDP-glucuronosyl -transferase: pharmacological implications [ J ]. Pharmacogenetics, 1997, 7(6) :485-495.

二级参考文献7

  • 1黄绍平,和光祖,陈征起,李瑞林,何娟,王锦秋,李丽.癫痫患儿丙戊酸钠药代动力学及稳态血药浓度的研究[J].中华儿科杂志,1994,32(2):89-91. 被引量:4
  • 2Krishnaswamy S, Hao Q, Al-Rohaimi A. UDP glucuronosyltransferase ( UGT ) 1A6 pharmacogenetics: I. Identification of polymorphisms in the 5'-reguhtory and exon 1 regions, and association with human liver UGT1A6 gene expression and glucuronidation. J Pharmacol Exp Ther,2005,313: 1331-1339.
  • 3Krishnaswamy S, Hao Q, AI-Rohaimi A. UDP glucuronosyltransferase ( UGT ) 1 A6 pharmacogenetics : II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A,T181A,and R184S). J Pharmacol Exp Ther, 2005,313 : 1340-1346.
  • 4Saeki M,Saito Y,Jinno H. Genetic polymorphisms of UGT1A6 in a Japanese population. Drug Metab Pharmacokinet ,2005,20:85-90.
  • 5Ferraro TN,Buono RJ. The relationship between the pharmacology of antiepileptic drugs and human gene variation: an overview. Epilepsy Behav,2005,7 : 18-36.
  • 6Nagar S, Zalatoris JJ, Blanchard RL. Human UGT1A6 pharmacogenetics: identification of a novel SNP, characterization of allele frequencies and functional analysis of recombinant allozymes in human liver tissue and in cultured cells. Pharmacogenetics ,2004,14:487-499.
  • 7郑惠良,祁元明,杨莹,黄喜顺,景学医,常爱武.血清丙戊酸钠浓度测定方法研究[J].河南医科大学学报,1997,32(4):78-80. 被引量:7

共引文献17

同被引文献109

引证文献10

二级引证文献45

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部